Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

Diversifying its manufacturing capabilities and improving supply chain resilience will be crucial for mitigating these risks. Novo Nordisk’s ... provide a clearer picture of investment ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

The three sites will expand our manufacturing capacity at scale and speed, while complementing our ongoing significant internal supply chain expansions," said Novo Nordisk's chief executive ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

In its fourth-quarter results statement, Novo Nordisk said that it had started to increase the supply of starting doses for Wegovy in the US since the start of the year thanks to those investments ...

An experimental obesity drug from Novo Nordisk resulted in 15.7% weight loss after 68 weeks of treatment — falling short of the company's expectations of 25% weight loss. The subcutaneous ...

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novo Nordisk’s GLP-1 drug Semaglutide, sold under brand names Ozempic and Wegovy, has been hailed as a miracle drug for treating obesity, with demand outpacing supply in key markets. Aster DM ...

Good morning, and welcome to the Kohl's Corporation fourth-quarter 2024 results conference call. All participants are in a listen-only mode. After the speakers' remarks, there will be a question ...